公司比較

簡介

CRISPR Therapeutics made history with the first FDA-approved CRISPR gene-editing therapy, Casgevy, for sickle cell disease. Co-founded by Nobel laureate Emmanuelle Charpentier, the company is leveraging its gene-editing platform across hematology, oncology (allogeneic CAR-T), and in vivo applications to create potentially curative one-time treatments.

營收

$0.4B

新聞缺口信號

此股票代碼沒有新聞缺口數據。

機構信號

此代號沒有13F信號記錄。

級聯模式

未出現在任何追蹤的級聯模式中。

關鍵關係

簡介

NVIDIA is the dominant designer of graphics processing units and AI accelerator chips. Its data-center GPU monopoly powers the generative-AI revolution, with the H100 and successor Blackwell GPUs serving as the de-facto standard for training and running large language models.

營收

$130.5B

新聞缺口信號

機構信號

級聯模式

關鍵關係